Intellia Therapeutics Share Price (NASDAQ: NTLA)

$11.43

▲

0.07

(0.62%)

Live

Last updated on August 28, 2025 at 12:37 am IST

$₹

Check the interactive Intellia Therapeutics Stock chart to analyse performance

Intellia Therapeutics stock performance

as on August 28, 2025 at 12:37 am IST

Today's Low:$11.37
Today's High:$11.63
$11.43
0.57%
Downside
Day's Volatility :2.28%
Upside
1.72%
52 Weeks Low:$5.90
52 Weeks High:$23.76
$11.43
48.38%
Downside
52 Weeks Volatility :75.17%
Upside
51.89%

Intellia Therapeutics Stock Returns

Period	Intellia Therapeutics Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	17.65%	3.7%	0.0%
6 Months	5.23%	-6.9%	0.0%
1 Year	-50.46%	-11.9%	0.0%
3 Years	-80.76%	7.7%	-6.9%

Intellia Therapeutics Inc. Key Stats

Check Intellia Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$11.36
Open	$11.55
Today's High	$11.63
Today's Low	$11.365
Market Capitalization	$1.2B
Today's Volume	$3.4M
52 Week High	$23.76
52 Week Low	$5.9
Revenue TTM	$52.9M
EBITDA	$-501.9M
Earnings Per Share (EPS)	$-4.69
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-56.95%

Stock Returns calculator for Intellia Therapeutics Stock including INR - Dollar returns

The Intellia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Intellia Therapeutics investment value today

Current value as on today

₹54,499

Returns

₹45,501

(-45.5%)

Returns from Intellia Therapeutics Stock

₹50,174 (-50.17%)

Dollar Returns*

₹4,673 (+4.67%)

Indian investors sentiment towards Intellia Therapeutics Stock

-20.73%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Investment in Intellia Therapeutics Shares from India has dropped by -20.73% over the past 30 days, indicating reduced transactional activity.

-24%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Intellia Therapeutics Stock from India on INDmoney has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Intellia Therapeutics Inc.

Name
Holdings %
Name
Holdings %
ARK Investment Management LLC
12.13%
Vanguard Group Inc
10.11%
BlackRock Inc
9.83%
State Street Corp
4.20%
Morgan Stanley - Brokerage Accounts
3.54%
Regeneron Pharmaceuticals Inc
3.45%

Analyst Recommendation on Intellia Therapeutics Stock

Rating

Trend

Buy

79%Buy

20%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Intellia Therapeutics(by analysts ranked 0 to 5 stars)

Intellia Therapeutics Share Price Target

What analysts predicted

Upside of 202.36%

Target:

$34.56

Current:

$11.43

Intellia Therapeutics share price target is $34.56, a slight Upside of 202.36% compared to current price of $11.43 as per analysts' prediction.

Intellia Therapeutics Stock Insights

Price Movement
In the last 7 days, NTLA stock has moved up by 11.3%
Decreasing Revenue
Revenue is down for the last 2 quarters, 16.62M → 14.24M (in $), with an average decrease of 14.3% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -146.97M → -101.25M (in $), with an average increase of 9.8% per quarter
NTLA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.0% return, outperforming this stock by 111.5%
NTLA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 113.9% return, outperforming this stock by 194.6%
Price to Sales
ForNTLA every $1 of sales, investors are willing to pay $22.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.7 for every $1 of sales.

Intellia Therapeutics Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$43.1M	↑ 41.63%
Net Income	$-99.5M	↑ 16.63%
Net Profit Margin	-230.92%	↑ 49.5%

	FY20	Y/Y Change
Revenue	$58.0M	↑ 34.55%
Net Income	$-125.6M	↑ 26.16%
Net Profit Margin	-216.52%	↑ 14.4%

	FY21	Y/Y Change
Revenue	$33.1M	↓ 43.01%
Net Income	$-259.7M	↑ 106.83%
Net Profit Margin	-785.76%	↓ 569.24%

	FY22	Y/Y Change
Revenue	$52.1M	↑ 57.69%
Net Income	$-474.2M	↑ 82.58%
Net Profit Margin	-909.78%	↓ 124.02%

	FY23	Y/Y Change
Revenue	$36.3M	↓ 30.4%
Net Income	$-481.2M	↑ 1.48%
Net Profit Margin	-1.3K%	↓ 416.73%

	FY24	Y/Y Change
Revenue	$57.9M	↑ 59.55%
Net Income	$-519.0M	↑ 7.86%
Net Profit Margin	-896.77%	↑ 429.74%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$28.9M	↓ 1609.39%
Net Income	$-107.4M	↓ 18.71%
Net Profit Margin	-371.3%	↓ 7265.46%

	Q2 FY24	Q/Q Change
Revenue	$7.0M	↓ 75.96%
Net Income	$-147.0M	↑ 36.8%
Net Profit Margin	-2.1K%	↓ 1741.32%

	Q3 FY24	Q/Q Change
Revenue	$9.1M	↑ 30.96%
Net Income	$-135.7M	↓ 7.66%
Net Profit Margin	-1.5K%	↑ 623.08%

	Q4 FY24	Q/Q Change
Revenue	$12.9M	↑ 41.3%
Net Income	$-128.9M	↓ 5.02%
Net Profit Margin	-1.0K%	↑ 488.31%

	Q1 FY25	Q/Q Change
Revenue	$16.6M	↑ 29.15%
Net Income	$-114.3M	↓ 11.3%
Net Profit Margin	-687.61%	↑ 313.62%

	Q2 FY25	Q/Q Change
Revenue	$14.2M	↓ 14.33%
Net Income	$-101.3M	↓ 11.44%
Net Profit Margin	-710.81%	↓ 23.2%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-65.3M	↓ 314.6%

	FY20	Y/Y Change
Profit	$58.0M	↓ 188.8%

	FY21	Y/Y Change
Profit	$33.1M	↓ 43.01%

	FY22	Y/Y Change
Profit	$44.5M	↑ 34.78%

	FY23	Y/Y Change
Profit	$27.3M	↓ 38.72%

	FY24	Y/Y Change
Profit	$47.6M	↑ 74.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$26.4M	↓ 702.85%

	Q2 FY24	Q/Q Change
Profit	$4.4M	↓ 83.51%

	Q3 FY24	Q/Q Change
Profit	$9.1M	↑ 109.06%

	Q4 FY24	Q/Q Change
Profit	$7.7M	↓ 15.49%

	Q1 FY25	Q/Q Change
Profit	$16.6M	↑ 115.94%

	Q2 FY25	Q/Q Change
Profit	$14.2M	↓ 14.33%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-103.2M	↑ 68.54%
Investing Cash Flow	$25.2M	↓ 109.65%
Financing Cash Flow	$76.4M	↑ 90.05%

	FY20	Y/Y Change
Operating Cash Flow	$-49.9M	↓ 51.65%
Investing Cash Flow	$-214.5M	↓ 951.95%
Financing Cash Flow	$371.8M	↑ 386.41%

	FY21	Y/Y Change
Operating Cash Flow	$-225.0M	↑ 350.85%
Investing Cash Flow	$-550.8M	↑ 156.79%
Financing Cash Flow	$736.7M	↑ 98.15%

	FY22	Y/Y Change
Operating Cash Flow	$-333.3M	↑ 48.11%
Investing Cash Flow	$160.3M	↓ 129.11%
Financing Cash Flow	$583.0M	↓ 20.87%

	FY23	Y/Y Change
Operating Cash Flow	$-394.1M	↑ 18.24%
Investing Cash Flow	$-31.3M	↓ 119.55%
Financing Cash Flow	$130.3M	↓ 77.64%

	FY24	Y/Y Change
Operating Cash Flow	$-348.9M	↓ 11.47%
Investing Cash Flow	$125.6M	↓ 500.57%
Financing Cash Flow	$185.7M	↑ 42.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-120.7M	↑ 29.67%
Investing Cash Flow	$5.9M	↓ 87.15%
Financing Cash Flow	$60.0M	↓ 43.66%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-58.2M	↓ 51.78%
Investing Cash Flow	$-24.2M	↓ 509.93%
Financing Cash Flow	$41.2M	↓ 31.25%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-84.8M	↑ 45.8%
Investing Cash Flow	$-7.7M	↓ 68.13%
Financing Cash Flow	$82.2M	↑ 99.27%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-85.2M	↑ 0.42%
Investing Cash Flow	$151.6M	↓ 2066.08%
Financing Cash Flow	$2.3M	↓ 97.18%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-148.9M	↑ 74.81%
Investing Cash Flow	$94.3M	↓ 37.76%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-99.6M	↓ 33.11%
Investing Cash Flow	$106.9M	↑ 13.34%
Financing Cash Flow	$14.7M	-

Intellia Therapeutics Technicals Summary

Sell

Neutral

Buy

Intellia Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Intellia Therapeutics Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Intellia Therapeutics Inc.	-13.31%	5.23%	-50.46%	-80.76%	-46.74%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.9%	-51.12%	-0.89%	-2.51%
Beone Medicines Ltd	4.54%	18.87%	52.28%	84.02%	26.72%
Vertex Pharmaceuticals Incorporated	-16.02%	-19.22%	-19.42%	37.43%	43.36%
Alnylam Pharmaceuticals, Inc.	38.9%	84.99%	60.96%	115.82%	243.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Intellia Therapeutics Inc.	NA	NA	-0.1	-4.1	-0.57	-0.31	NA	6.79
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.64	27.64	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Intellia Therapeutics Inc.	Buy	$1.2B	-46.74%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-2.51%	14.86	31.37%
Beone Medicines Ltd	NA	$38.3B	26.72%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.7B	43.36%	27.64	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.2B	243.29%	NA	-12.96%

Intellia Therapeutics Dividend announcements

Intellia Therapeutics Earnings
Intellia Therapeutics’s price-to-earnings ratio stands at None

About Intellia Therapeutics Inc.

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organization	Intellia Therapeutics
Employees	403
CEO	Dr. Laura Sepp-Lorenzino Ph.D.
Industry	Health Technology

Key Management of Intellia Therapeutics Inc.

Name	Title
Dr. John M. Leonard M.D.	President, CEO & Director
Mr. Edward J. Dulac III	Executive Vice President, Chief Financial Officer and Treasurer
Mr. Michael P. Dube	VP, CAO & Principal Accounting Officer
Mr. James E. Basta Esq., J.D.	Executive VP, General Counsel & Corporate Secretary
Dr. Laura Sepp-Lorenzino Ph.D.	Special Advisor to the Chief Executive Officer
Dr. David Lebwohl M.D.	Executive VP & Chief Medical Officer
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder
Dr. Jennifer A. Doudna Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Derrick J. Rossi Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Rodolphe Barrangou M.B.A., Ph.D.	Founder & Member of Scientific Advisor Board

Important FAQs about investing in NTLA Stock from India :

What is Intellia Therapeutics share price today?

Intellia Therapeutics share price today is $11.43 as on August 28, 2025 at 12:37 am IST. Intellia Therapeutics share today touched a day high of $11.63 and a low of $11.37.

What is the 52 week high and 52 week low for Intellia Therapeutics share?

Intellia Therapeutics share touched a 52 week high of $23.76 and a 52 week low of $5.90. Intellia Therapeutics stock price today i.e. August 28, 2025 at 12:37 am IST is trending at $11.43, lower by 51.89% versus the 52 week high.

How to invest in Intellia Therapeutics Stock (NTLA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Intellia Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Intellia Therapeutics Shares that will get you 0.1312 shares as per Intellia Therapeutics share price of $11.43 per share as on August 28, 2025 at 12:37 am IST.

What is the minimum amount required to buy Intellia Therapeutics Stock (NTLA) from India?

Indian investors can start investing in Intellia Therapeutics (NTLA) shares with as little as ₹87.86 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Intellia Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Intellia Therapeutics share’s latest price of $11.43 as on August 28, 2025 at 12:37 am IST, you will get 0.8749 shares of Intellia Therapeutics. Learn more about fractional shares .

What are the returns that Intellia Therapeutics has given to Indian investors in the last 5 years?

Intellia Therapeutics stock has given -46.74% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?